Metropolitan Life Insurance Company (MetLife)’s Arbutus Biopharma ABUS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,340	Closed	-$11.2K	–	23
2024 Q1	$11.2K	Buy	4,340 +1,386	+47%	+$3.59K	﹤0.01%	2093
2023 Q4	$7.38K	Sell	2,954 -3,255	-52%	-$6.38K	﹤0.01%	2254
2023 Q3	$12.6K	Hold	6,209	–	–	﹤0.01%	2112
2023 Q2	$14.3K	Hold	6,209	–	–	﹤0.01%	2108
2023 Q1	$18.8K	Sell	6,209 -384	-6%	-$1.08K	﹤0.01%	1915
2022 Q4	$15.4K	Hold	6,593	–	–	﹤0.01%	2123
2022 Q3	$12.6K	Buy	6,593 +4,768	+261%	+$11.2K	﹤0.01%	2228
2022 Q2	$4.95K	Sell	1,825 -3,784	-67%	-$9.68K	﹤0.01%	2339
2022 Q1	$16.7K	Sell	5,609 -13,522	-71%	-$41.4K	﹤0.01%	2171
2021 Q4	$74.4K	Sell	19,131 -3,597	-16%	-$14K	﹤0.01%	2616
2021 Q3	$97.5K	Buy	+22,728	New	+$75.7K	﹤0.01%	2534
2018 Q4	–	Sell	-12,790	Closed	-$121K	–	2547
2018 Q3	$121K	Buy	+12,790	New	+$127K	﹤0.01%	2343

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ABUS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Arbutus Biopharma (ABUS) in Q2 2024, closing a stake of 4,340 shares — an estimated $11.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ABUS in Q3 2018 and held it in 12 quarters. The position peaked at $121K in Q3 2018. 131 funds tracked by Wall St. Rank hold ABUS as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Arbutus Biopharma position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 4,340 Arbutus Biopharma shares in Q2 2024, an estimated $11.2K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Arbutus Biopharma in Q3 2018 and held it in 12 quarters.
Metropolitan Life Insurance Company (MetLife)'s Arbutus Biopharma position peaked at $121K in Q3 2018.
131 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.